APLS Quote, Financials, Valuation and Earnings

Ardelyx has a net margin of -55.29% compared to Apellis Pharmaceuticals's net margin of -55.52%. Apellis Pharmaceuticals's return on equity of -96.34% beat Ardelyx's return on equity of -34.68%.

Apellis Pharmaceuticals has a consensus price target of $35.45, signalling upside risk potential of 76.9%. On the other hand Ardelyx has an analysts' consensus of $10.91 which suggests that it could grow by 141.35%. Given that Ardelyx has higher upside potential than Apellis Pharmaceuticals, analysts believe Ardelyx is more attractive than Apellis Pharmaceuticals.

Apellis Pharmaceuticals has a beta of 0.673, which suggesting that the stock is 32.72% less volatile than S&P 500. In comparison Ardelyx has a beta of 0.605, suggesting its less volatile than the S&P 500 by 39.538%.

Apellis Pharmaceuticals has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Ardelyx offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Apellis Pharmaceuticals pays -- of its earnings as a dividend. Ardelyx pays out -- of its earnings as a dividend.

Apellis Pharmaceuticals quarterly revenues are $166.8M, which are larger than Ardelyx quarterly revenues of $74.1M. Apellis Pharmaceuticals's net income of -$92.2M is lower than Ardelyx's net income of -$41.1M. Notably, Apellis Pharmaceuticals's price-to-earnings ratio is -- while Ardelyx's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Apellis Pharmaceuticals is 3.22x versus 2.96x for Ardelyx. Usually stocks with elevated PS ratios are considered overvalued.

Rhythm Pharmaceuticals has a net margin of -55.29% compared to Apellis Pharmaceuticals's net margin of -151.35%. Apellis Pharmaceuticals's return on equity of -96.34% beat Rhythm Pharmaceuticals's return on equity of -116.92%.

Apellis Pharmaceuticals has a consensus price target of $35.45, signalling upside risk potential of 76.9%. On the other hand Rhythm Pharmaceuticals has an analysts' consensus of $103.64 which suggests that it could grow by 13.35%. Given that Apellis Pharmaceuticals has higher upside potential than Rhythm Pharmaceuticals, analysts believe Apellis Pharmaceuticals is more attractive than Rhythm Pharmaceuticals.

Apellis Pharmaceuticals has a beta of 0.673, which suggesting that the stock is 32.72% less volatile than S&P 500. In comparison Rhythm Pharmaceuticals has a beta of 2.265, suggesting its more volatile than the S&P 500 by 126.541%.

Apellis Pharmaceuticals has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Rhythm Pharmaceuticals offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Apellis Pharmaceuticals pays -- of its earnings as a dividend. Rhythm Pharmaceuticals pays out -- of its earnings as a dividend.

Apellis Pharmaceuticals quarterly revenues are $166.8M, which are larger than Rhythm Pharmaceuticals quarterly revenues of $32.7M. Apellis Pharmaceuticals's net income of -$92.2M is lower than Rhythm Pharmaceuticals's net income of -$49.5M. Notably, Apellis Pharmaceuticals's price-to-earnings ratio is -- while Rhythm Pharmaceuticals's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Apellis Pharmaceuticals is 3.22x versus 41.24x for Rhythm Pharmaceuticals. Usually stocks with elevated PS ratios are considered overvalued.

TG Therapeutics has a net margin of -55.29% compared to Apellis Pharmaceuticals's net margin of 4.19%. Apellis Pharmaceuticals's return on equity of -96.34% beat TG Therapeutics's return on equity of 19.78%.

Apellis Pharmaceuticals has a consensus price target of $35.45, signalling upside risk potential of 76.9%. On the other hand TG Therapeutics has an analysts' consensus of $40.50 which suggests that it could grow by 4.27%. Given that Apellis Pharmaceuticals has higher upside potential than TG Therapeutics, analysts believe Apellis Pharmaceuticals is more attractive than TG Therapeutics.

Apellis Pharmaceuticals has a beta of 0.673, which suggesting that the stock is 32.72% less volatile than S&P 500. In comparison TG Therapeutics has a beta of 1.913, suggesting its more volatile than the S&P 500 by 91.257%.

Apellis Pharmaceuticals has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. TG Therapeutics offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Apellis Pharmaceuticals pays -- of its earnings as a dividend. TG Therapeutics pays out -- of its earnings as a dividend.

Apellis Pharmaceuticals quarterly revenues are $166.8M, which are larger than TG Therapeutics quarterly revenues of $120.9M. Apellis Pharmaceuticals's net income of -$92.2M is lower than TG Therapeutics's net income of $5.1M. Notably, Apellis Pharmaceuticals's price-to-earnings ratio is -- while TG Therapeutics's PE ratio is 161.83x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Apellis Pharmaceuticals is 3.22x versus 16.16x for TG Therapeutics. Usually stocks with elevated PS ratios are considered overvalued.

Vertex Pharmaceuticals has a net margin of -55.29% compared to Apellis Pharmaceuticals's net margin of 23.33%. Apellis Pharmaceuticals's return on equity of -96.34% beat Vertex Pharmaceuticals's return on equity of -6.04%.

Apellis Pharmaceuticals has a consensus price target of $35.45, signalling upside risk potential of 76.9%. On the other hand Vertex Pharmaceuticals has an analysts' consensus of $500.30 which suggests that it could grow by 6.55%. Given that Apellis Pharmaceuticals has higher upside potential than Vertex Pharmaceuticals, analysts believe Apellis Pharmaceuticals is more attractive than Vertex Pharmaceuticals.

Apellis Pharmaceuticals has a beta of 0.673, which suggesting that the stock is 32.72% less volatile than S&P 500. In comparison Vertex Pharmaceuticals has a beta of 0.410, suggesting its less volatile than the S&P 500 by 59.044%.

Apellis Pharmaceuticals has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Vertex Pharmaceuticals offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Apellis Pharmaceuticals pays -- of its earnings as a dividend. Vertex Pharmaceuticals pays out -- of its earnings as a dividend.

Apellis Pharmaceuticals quarterly revenues are $166.8M, which are smaller than Vertex Pharmaceuticals quarterly revenues of $2.8B. Apellis Pharmaceuticals's net income of -$92.2M is lower than Vertex Pharmaceuticals's net income of $646.3M. Notably, Apellis Pharmaceuticals's price-to-earnings ratio is -- while Vertex Pharmaceuticals's PE ratio is 26.10x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Apellis Pharmaceuticals is 3.22x versus 10.96x for Vertex Pharmaceuticals. Usually stocks with elevated PS ratios are considered overvalued.